Interstitial pneumonitis associated with infliximab therapy.
Interstitial pneumonitis is a well documented, rare complication of methotrexate (MTX). We describe a patient with rheumatoid arthritis (RA) taking MTX for more than 3 years who then developed severe interstitial pneumonitis after a third infliximab infusion. Other similar cases are reviewed. Infliximab may potentiate pulmonary toxicity of MTX.
Villeneuve
Edith
E
Department of Rheumatology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
St-Pierre
Anne
A
Haraoui
Boulos
B
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D011239:Prednisolone / Q000627:therapeutic use; D013902:Radiography, Thoracic
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D011239:Prednisolone; D000069285:Infliximab; D008727:Methotrexate